Cargando…

Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma

The multityrosine kinase inhibitor sorafenib remains an important systemic treatment option for hepatocellular carcinoma (HCC). Signaling pathways, which are targeted by sorafenib, are involved in checkpoint and DNA repair response, RAD51 being a candidate protein. Here, we aim to evaluate the effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samadaei, Mahzeiar, Senfter, Daniel, Madlener, Sibylle, Uranowska, Karolina, Hafner, Christine, Trauner, Michael, Rohr‐Udilova, Nataliya, Pinter, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828257/ https://www.ncbi.nlm.nih.gov/pubmed/36271841 http://dx.doi.org/10.1002/jcb.30340

Ejemplares similares

Cytotoxic Activity of Piperazin-2-One-Based Structures: Cyclic Imines, Lactams, Aminophosphonates, and Their Derivatives
por: Iwanejko, Jakub, et al.
Publicado: (2021)

Synthesis and Cytotoxic Activity of Chiral Sulfonamides Based on the 2-Azabicycloalkane Skeleton
por: Samadaei, Mahzeiar, et al.
Publicado: (2020)

A chondroitin sulfate proteoglycan 4-specific monoclonal antibody inhibits melanoma cell invasion in a spheroid model
por: Uranowska, Karolina, et al.
Publicado: (2021)

High impact of miRNA-4521 on FOXM1 expression in medulloblastoma
por: Senfter, Daniel, et al.
Publicado: (2019)

Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma
por: Rohr-Udilova, Nataliya, et al.
Publicado: (2018)

Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma
por: Rohr-Udilova, Nataliya, et al.
Publicado: (2018)

Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib
por: Rohr-Udilova, Nataliya, et al.
Publicado: (2017)

Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2020)

Morphometric Analysis of Mast Cells in Tumor Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation
por: Rohr‐Udilova, Nataliya, et al.
Publicado: (2021)

Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2021)

Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF
por: Uranowska, Karolina, et al.
Publicado: (2021)

Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma
por: Grossauer, Anna, et al.
Publicado: (2023)

Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma
por: Almhanna, Khaldoun, et al.
Publicado: (2009)

Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma
por: Lee, Sangheun, et al.
Publicado: (2013)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
por: Kang, Seong Hee, et al.
Publicado: (2018)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma
por: Marta, Guilherme Nader, et al.
Publicado: (2021)

Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram
por: Zhang, Gong, et al.
Publicado: (2022)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma
por: NISHIKAWA, HIROKI, et al.
Publicado: (2012)

Tenofovir Hampers the Efficacy of Sorafenib in Prolonging Overall Survival in Hepatocellular Carcinoma
por: Liang, Kung-Hao, et al.
Publicado: (2021)

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma
por: Wu, Fei-Xiang, et al.
Publicado: (2017)

The impact of thyroid hormones on patients with hepatocellular carcinoma
por: Pinter, Matthias, et al.
Publicado: (2017)

Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability
por: Køstner, Anne Helene, et al.
Publicado: (2013)

Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis
por: Shang, Jin, et al.
Publicado: (2017)

Efficacy of on-demand intrahepatic arterial therapy in combination with sorafenib for advanced hepatocellular carcinoma
por: Tajiri, Kazuto, et al.
Publicado: (2019)

The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Chen, Lei, et al.
Publicado: (2021)

Strategies to improve sorafenib efficacy during image-guided treatment of hepatocellular carcinoma
por: Eresen, Aydin, et al.
Publicado: (2021)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib
por: da Fonseca, Leonardo Gomes, et al.
Publicado: (2018)

Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma
por: Yoo, Jeong-Ju, et al.
Publicado: (2019)

A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection
por: Huang, Shenglan, et al.
Publicado: (2021)

Cerebrovascular Accidents Associated with Sorafenib in Hepatocellular Carcinoma
por: Saif, Muhammad W., et al.
Publicado: (2011)

Evolving role of Sorafenib in the management of hepatocellular carcinoma
por: Ziogas, Ioannis A, et al.
Publicado: (2017)

Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_illtees90o3o050r0s4k20rk9v